Welcome to N4 Pharma
We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Watch our video animation below to see Nuvec® in action:
Information for investors
Are you an investor? Visit the dedicated area of the website to view information on the AIM rule 26, company presentations and reports. The latest regulatory news updates are also available.
Nuvec® is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments. It’s currently in the pre-clinical phase and you can download our whitepaper to read all about its mode of action, plus watch our Nuvec® animation!
Latest news and updates
Nuvec® form and function: nanotopography matters
Over the last three decades, rapid progress in molecular biology has led to nucleic acids, such as plasmid DNA (pDNA), messenger RNA (mRNA) and, small interfering/silencing RNA (siRNA), being proposed for use as therapeutic agents. [...]
N4 Pharma and Proactive discuss the latest update on Nuvec®
Our CEO, Nigel Theobald, recently provided an update on our Nuvec® program following the release of our interim results. You can watch the full interview with Proactive London's Andrew Scott below or visit the website: [...]
Catching up with The Medicine Maker
Our CEO, Nigel Theobald, recently caught up with The Medicine Maker to discuss the story behind N4 Pharma and give his advice to entrepreneurs in the pharmaceutical industry. Click here to create your logins and [...]